Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: Analysis of a randomized, open-label study

Schizophrenia Research

Volumn 107, Issue 2-3, 2009, Pages 218-222

  Byerly, Matthew J ^a   Marcus, Ronald N ^b   Tran, Quynh Van ^c   Eudicone, James M ^b   Whitehead, Richard ^c   Baker, Ross A ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

Aripiprazole; Olanzapine; Prolactin; Risperidone; Switching

Indexed keywords

ARIPIPRAZOLE; OLANZAPINE; PROLACTIN; RISPERIDONE;

AGITATION; AKATHISIA; ANXIETY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; HYPERPROLACTINEMIA; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; NAUSEA; OPEN STUDY; OUTPATIENT; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPERPROLACTINEMIA; MALE; MIDDLE AGED; PIPERAZINES; PROLACTIN; PSYCHOTIC DISORDERS; QUINOLONES; RISPERIDONE; SCHIZOPHRENIA; SEX FACTORS; SUBSTANCE WITHDRAWAL SYNDROME; YOUNG ADULT;

EID: 58249085773     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2008.09.019     Document Type: Article

References (21)

1. Burris K.D., Molski T.F., Xu C., Ryan E., Tottori K., Kikuchi T., Yocca F.D., and Molinoff P.B. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J. Pharmacol. Exp. Ther. 302 1 (2002) 381-389
2. Byerly M., Suppes T., Tran Q.V., and Baker R.A. Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives. J. Clin. Psychopharmacol. 27 6 (2007) 639-661
3. Casey D.E., Carson W.H., Saha A.R., Liebeskind A., Ali M.W., Jody D., and Ingenito G.G. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berl.) 166 4 (2003) 391-399
4. El-Sayeh H.G., and Morganti C. Aripiprazole for schizophrenia. Cochrane Database Syst. Rev. 2 (2006) CD004578
5. Halbreich U., and Kahn L. Hyperprolactinemia and schizophrenia: mechanisms and clinical aspects. J. Psychiatr. Pract. 9 5 (2003) 344-353
6. Kane J.M., Carson W.H., Saha A.R., McQuade R.D., Ingenito G.G., Zimbroff D.L., and Ali M.W. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J. Clin. Psychiatry 63 9 (2002) 763-771
7. Kasper S., Lerman M.N., McQuade R.D., Saha A., Carson W.H., Ali M., Archibald D., Ingenito G., Marcus R., and Pigott T. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int. J. Neuropsychopharmacol. 6 4 (2003) 325-337
8. Kishimoto T., Watanabe K., Shimada N., Makita K., Yagi G., and Kashima H. Antipsychotic-induced hyperprolactinemia inhibits the hypothalamo-pituitary-gonadal axis and reduces bone mineral density in male patients with schizophrenia. J. Clin. Psychiatry (2008) e1-e7
9. Knegtering H., van der Moolen A.E., Castelein S., Kluiter H., and van den Bosch R.J. What are the effects of antipsychotics on sexual dysfunctions and endocrine functioning?. Psychoneuroendocrinology 28 Suppl 2 (2003) 109-123
10. Lee B.H., Kim Y.K., and Park S.H. Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: a pilot study. Prog. Neuropsychopharmacol. Biol. Psychiatry 30 4 (2006) 714-717
11. Lin S.K., and Chen C.K. Reversal of antipsychotic-induced hyperprolactinemia, weight gain, and dyslipidemia by aripiprazole: a case report. J. Clin. Psychiatry 67 8 (2006) 1307
12. Marder S.R., McQuade R.D., Stock E., Kaplita S., Marcus R., Safferman A.Z., Saha A., Ali M., and Iwamoto T. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr. Res. 61 2-3 (2003) 123-136
13. Meaney A.M., Smith S., Howes O.D., O'Brien M., Murray R.M., and O'Keane V. Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia. Br. J. Psychiatry 184 (2004) 503-508
14. Naidoo U., Goff D.C., and Klibanski A. Hyperprolactinemia and bone mineral density: the potential impact of antipsychotic agents. Psychoneuroendocrinology 28 Suppl. 2 (2003) 97-108
15. Pigott T.A., Carson W.H., Saha A.R., Torbeyns A.F., Stock E.G., and Ingenito G.G. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J. Clin. Psychiatry 64 9 (2003) 1048-1056
16. Potkin S.G., Saha A.R., Kujawa M.J., Carson W.H., Ali M., Stock E., Stringfellow J., Ingenito G., and Marder S.R. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch. Gen. Psychiatry 60 7 (2003) 681-690
17. Shim J.C., Shin J.G., Kelly D.L., Jung D.U., Seo Y.S., Liu K.H., Shon J.H., and Conley R.R. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. Am. J. Psychiatry 164 9 (2007) 1404-1410
18. Szarfman A., Tonning J.M., Levine J.G., and Doraiswamy P.M. Atypical antipsychotics and pituitary tumors: a pharmacovigilance study. Pharmacotherapy 26 6 (2006) 748-758
19. Wahl R., and Ostroff R. Reversal of symptomatic hyperprolactinemia by aripiprazole. Am. J. Psychiatry 162 8 (2005) 1542-1543
20. Wieck A., and Haddad P.M. Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences. Selective literature review. Br. J. Psychiatry 182 (2003) 199-204
21. Wolf J., and Fiedler U. Hyperprolactinemia and amenorrhea associated with olanzapine normalized after addition of aripiprazole. J. Clin. Pharm. Ther. 32 2 (2007) 197-198